Drugs / cardiomyopeptidin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06155110 | Nov 2019 → Mar 2025 | cardiovascular disorder | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03958422 | Jun → Nov 2019 | acute myocardial infarction | Dalian Zhen-Ao Bio-Tech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cardiomyopeptidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03958422 ↗ |
| Route | Intravenous | “intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI” NCT03958422 ↗ |